BRKR). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BRKR. The Company posted its financial results on February 08, 2018, for the fourth quarter of the fiscal year 2017 (Q4 FY17) and for the full fiscal year 2017 (FY17). The Billerica, Massachusetts-based Company reported a 12.8% and 11% y-o-y growth in its quarterly revenues and non-GAAP diluted EPS; outperforming market expectations. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Analogic Corporation (NASDAQ: ALOG), which also belongs to the Healthcare sector as the Company Bruker. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=ALOG

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Bruker most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=BRKR

Earnings Highlights and Summary

For the three months ended December 31, 2017, Bruker reported revenues of $530.5 million, above the $470.3 million recorded at the end of Q4 FY16. The Company's revenue numbers for the reported quarter beat market forecasts of $507.5 million. Furthermore, the Company's organic revenue growth was 4.0%, while growth from acquisitions was 3.6% and the favorable effect of changes in foreign currency rates was 5.2%.

The scientific equipment maker reported a net loss attributable to common shareholders of $3.4 million, or $0.02 loss per diluted share, in Q4 FY17 compared to a net income attributable to common shareholders of $69.0 million, or $0.43 per diluted share, in Q4 FY16. Meanwhile, the Company posted a non-GAAP net income attributable to common shareholders of $79.8 million, or $0.51 per diluted share, in Q4 FY17, up from $73.7 million, or $0.46 per diluted share, in the same quarter of last year. Moreover, Wall Street had expected the Company to report a non-GAAP net income of $0.49 per diluted share for Q4 FY17.

For the full year FY17, Bruker's revenues came in at $1.77 billion, rising from $1.61 billion in FY16. The Company's net income attributable to common shareholders stood at $78.6 million, or $0.49 per diluted share, in FY17 versus $153.6 million, or $0.95 per diluted share, in FY16. Additionally, the Company's non-GAAP net income attributable to common shareholders grew to $192.2 million, or $1.21 per share, in FY17, up from $192.3 million, or $1.19 per diluted share, in the last year's comparable period.

Operating Metrics

In the three months ended December 31, 2017, Bruker reported the cost of revenues of $275.3 million compared to $249.9 million in Q4 FY16. The Company's non-GAAP gross profit improved to $265.0 million, or 50.0% of revenues, during Q4 FY17 from $229.5 million, or 48.8% of revenues, in Q4 FY16.

During the reported quarter, Bruker's research and development (R&D) expenses came in at $43.5 million versus $38.2 million in the last year's comparable quarter. The Company's selling, general, and administrative expenses (SG&A) were $112.1 million during Q4 FY17 versus $100.1 million in Q4 FY16. The Company's total operating expenses came in at $161.5 million in the reported quarter compared to $143.5 million in Q4 FY16. The Company reported a non-GAAP operating income of $110.8 million, or 20.9% of revenues, in Q4 FY17 compared to $92.0 million, or 19.6% of revenues, in Q4 FY16. Meanwhile, the Company's non-GAAP profit before tax rose to $106.2 million during Q4 FY17 from $94.3 million in Q4 FY16.

Cash Flow and Balance Sheet

During the fourth quarter ended December 31, 2017, Bruker generated $103.7 million in cash from operations versus $90.8 million in the fourth quarter of the fiscal year 2016. The Company's free cash flow was $91.3 million in Q4 FY17 compared to $79.7 million in the previous year's corresponding quarter.

Bruker's cash and cash equivalents balance was $325.0 million as on December 31, 2017, compared to $342.4 million as on December 31, 2016. Furthermore, the Company's long-term debt stood at $415.6 million as on December 31, 2017, compared to $391.6 million as on December 31, 2016.

Outlook

In its guidance for FY18, Bruker expects a revenue growth of approximately 7%, which includes an organic revenue growth of approximately 3%, and a foreign currency revenue tailwind of approximately 4%. The Company's non-GAAP operating margin is expected to improve by 50 bps and 80bps for FY18. The management further anticipates non-GAAP earnings per share to be in the range of $1.34 and $1.38 during FY18, rising 11% to 14% y-o-y.

Dividend

In a separate press on February 20, 2018, Bruker's Board of Directors announced a quarterly cash dividend in the amount of $0.04 per share on its common stock. The dividend will be paid on March 23, 2018, to stockholders of record as of March 06, 2018.

Stock Performance Snapshot

March 13, 2018 - At Tuesday's closing bell, Bruker's stock fell 1.98%, ending the trading session at $30.13.

Volume traded for the day: 1.08 million shares, which was above the 3-month average volume of 508.40 thousand shares.

Stock performance in the previous six-month period – up 0.94%; and past twelve-month period – up 26.86%

After yesterday's close, Bruker's market cap was at $4.60 billion.

Price to Earnings (P/E) ratio was at 32.26.

The stock has a dividend yield of 0.53%.

The stock is part of the Healthcare sector, categorized under the Medical Laboratories & Research industry.

Active-Investors :

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 492981

"/> Free Post Earnings Research Report: Bruker’s Q4 Top-Line Grew 12.8% Y-o-Y; Outshone Expectations « MarketersMedia – Press Release Distribution Services – News Release Distribution Services
Great News! MarketersMedia is officially entering into a long-term partnership with Vertical News Network.
Learn More
How It Works? Plans & Pricing Our Distributions Newsroom Info Hub Sign Up Sign In Send Press Release Contact Sales
Contact Sales Sign Up Your Account Send Press Release
MarketersMEDIA / Newsroom / Free Post Earnings Research Report: Bruker’s Q4 Top-Line Grew 12.8% Y-o-Y; Outshone Expectations

Free Post Earnings Research Report: Bruker’s Q4 Top-Line Grew 12.8% Y-o-Y; Outshone Expectations

Share This Press Release

Stock Monitor: Analogic Post Earnings Reporting

LONDON, UK / ACCESSWIRE / March 14, 2018 / Active-Investors.com has just released a free earnings report on Bruker Corp. (NASDAQ: BRKR). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BRKR. The Company posted its financial results on February 08, 2018, for the fourth quarter of the fiscal year 2017 (Q4 FY17) and for the full fiscal year 2017 (FY17). The Billerica, Massachusetts-based Company reported a 12.8% and 11% y-o-y growth in its quarterly revenues and non-GAAP diluted EPS; outperforming market expectations. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Analogic Corporation (NASDAQ: ALOG), which also belongs to the Healthcare sector as the Company Bruker. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=ALOG

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Bruker most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=BRKR

Earnings Highlights and Summary

For the three months ended December 31, 2017, Bruker reported revenues of $530.5 million, above the $470.3 million recorded at the end of Q4 FY16. The Company's revenue numbers for the reported quarter beat market forecasts of $507.5 million. Furthermore, the Company's organic revenue growth was 4.0%, while growth from acquisitions was 3.6% and the favorable effect of changes in foreign currency rates was 5.2%.

The scientific equipment maker reported a net loss attributable to common shareholders of $3.4 million, or $0.02 loss per diluted share, in Q4 FY17 compared to a net income attributable to common shareholders of $69.0 million, or $0.43 per diluted share, in Q4 FY16. Meanwhile, the Company posted a non-GAAP net income attributable to common shareholders of $79.8 million, or $0.51 per diluted share, in Q4 FY17, up from $73.7 million, or $0.46 per diluted share, in the same quarter of last year. Moreover, Wall Street had expected the Company to report a non-GAAP net income of $0.49 per diluted share for Q4 FY17.

For the full year FY17, Bruker's revenues came in at $1.77 billion, rising from $1.61 billion in FY16. The Company's net income attributable to common shareholders stood at $78.6 million, or $0.49 per diluted share, in FY17 versus $153.6 million, or $0.95 per diluted share, in FY16. Additionally, the Company's non-GAAP net income attributable to common shareholders grew to $192.2 million, or $1.21 per share, in FY17, up from $192.3 million, or $1.19 per diluted share, in the last year's comparable period.

Operating Metrics

In the three months ended December 31, 2017, Bruker reported the cost of revenues of $275.3 million compared to $249.9 million in Q4 FY16. The Company's non-GAAP gross profit improved to $265.0 million, or 50.0% of revenues, during Q4 FY17 from $229.5 million, or 48.8% of revenues, in Q4 FY16.

During the reported quarter, Bruker's research and development (R&D) expenses came in at $43.5 million versus $38.2 million in the last year's comparable quarter. The Company's selling, general, and administrative expenses (SG&A) were $112.1 million during Q4 FY17 versus $100.1 million in Q4 FY16. The Company's total operating expenses came in at $161.5 million in the reported quarter compared to $143.5 million in Q4 FY16. The Company reported a non-GAAP operating income of $110.8 million, or 20.9% of revenues, in Q4 FY17 compared to $92.0 million, or 19.6% of revenues, in Q4 FY16. Meanwhile, the Company's non-GAAP profit before tax rose to $106.2 million during Q4 FY17 from $94.3 million in Q4 FY16.

Cash Flow and Balance Sheet

During the fourth quarter ended December 31, 2017, Bruker generated $103.7 million in cash from operations versus $90.8 million in the fourth quarter of the fiscal year 2016. The Company's free cash flow was $91.3 million in Q4 FY17 compared to $79.7 million in the previous year's corresponding quarter.

Bruker's cash and cash equivalents balance was $325.0 million as on December 31, 2017, compared to $342.4 million as on December 31, 2016. Furthermore, the Company's long-term debt stood at $415.6 million as on December 31, 2017, compared to $391.6 million as on December 31, 2016.

Outlook

In its guidance for FY18, Bruker expects a revenue growth of approximately 7%, which includes an organic revenue growth of approximately 3%, and a foreign currency revenue tailwind of approximately 4%. The Company's non-GAAP operating margin is expected to improve by 50 bps and 80bps for FY18. The management further anticipates non-GAAP earnings per share to be in the range of $1.34 and $1.38 during FY18, rising 11% to 14% y-o-y.

Dividend

In a separate press on February 20, 2018, Bruker's Board of Directors announced a quarterly cash dividend in the amount of $0.04 per share on its common stock. The dividend will be paid on March 23, 2018, to stockholders of record as of March 06, 2018.

Stock Performance Snapshot

March 13, 2018 - At Tuesday's closing bell, Bruker's stock fell 1.98%, ending the trading session at $30.13.

Volume traded for the day: 1.08 million shares, which was above the 3-month average volume of 508.40 thousand shares.

Stock performance in the previous six-month period – up 0.94%; and past twelve-month period – up 26.86%

After yesterday's close, Bruker's market cap was at $4.60 billion.

Price to Earnings (P/E) ratio was at 32.26.

The stock has a dividend yield of 0.53%.

The stock is part of the Healthcare sector, categorized under the Medical Laboratories & Research industry.

Active-Investors :

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 492981

Stock Monitor: Analogic Post Earnings Reporting

LONDON, UK / ACCESSWIRE / March 14, 2018 / Active-Investors.com has just released a free earnings report on Bruker Corp. (NASDAQ: BRKR). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BRKR. The Company posted its financial results on February 08, 2018, for the fourth quarter of the fiscal year 2017 (Q4 FY17) and for the full fiscal year 2017 (FY17). The Billerica, Massachusetts-based Company reported a 12.8% and 11% y-o-y growth in its quarterly revenues and non-GAAP diluted EPS; outperforming market expectations. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Analogic Corporation (NASDAQ: ALOG), which also belongs to the Healthcare sector as the Company Bruker. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=ALOG

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Bruker most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=BRKR

Earnings Highlights and Summary

For the three months ended December 31, 2017, Bruker reported revenues of $530.5 million, above the $470.3 million recorded at the end of Q4 FY16. The Company's revenue numbers for the reported quarter beat market forecasts of $507.5 million. Furthermore, the Company's organic revenue growth was 4.0%, while growth from acquisitions was 3.6% and the favorable effect of changes in foreign currency rates was 5.2%.

The scientific equipment maker reported a net loss attributable to common shareholders of $3.4 million, or $0.02 loss per diluted share, in Q4 FY17 compared to a net income attributable to common shareholders of $69.0 million, or $0.43 per diluted share, in Q4 FY16. Meanwhile, the Company posted a non-GAAP net income attributable to common shareholders of $79.8 million, or $0.51 per diluted share, in Q4 FY17, up from $73.7 million, or $0.46 per diluted share, in the same quarter of last year. Moreover, Wall Street had expected the Company to report a non-GAAP net income of $0.49 per diluted share for Q4 FY17.

For the full year FY17, Bruker's revenues came in at $1.77 billion, rising from $1.61 billion in FY16. The Company's net income attributable to common shareholders stood at $78.6 million, or $0.49 per diluted share, in FY17 versus $153.6 million, or $0.95 per diluted share, in FY16. Additionally, the Company's non-GAAP net income attributable to common shareholders grew to $192.2 million, or $1.21 per share, in FY17, up from $192.3 million, or $1.19 per diluted share, in the last year's comparable period.

Operating Metrics

In the three months ended December 31, 2017, Bruker reported the cost of revenues of $275.3 million compared to $249.9 million in Q4 FY16. The Company's non-GAAP gross profit improved to $265.0 million, or 50.0% of revenues, during Q4 FY17 from $229.5 million, or 48.8% of revenues, in Q4 FY16.

During the reported quarter, Bruker's research and development (R&D) expenses came in at $43.5 million versus $38.2 million in the last year's comparable quarter. The Company's selling, general, and administrative expenses (SG&A) were $112.1 million during Q4 FY17 versus $100.1 million in Q4 FY16. The Company's total operating expenses came in at $161.5 million in the reported quarter compared to $143.5 million in Q4 FY16. The Company reported a non-GAAP operating income of $110.8 million, or 20.9% of revenues, in Q4 FY17 compared to $92.0 million, or 19.6% of revenues, in Q4 FY16. Meanwhile, the Company's non-GAAP profit before tax rose to $106.2 million during Q4 FY17 from $94.3 million in Q4 FY16.

Cash Flow and Balance Sheet

During the fourth quarter ended December 31, 2017, Bruker generated $103.7 million in cash from operations versus $90.8 million in the fourth quarter of the fiscal year 2016. The Company's free cash flow was $91.3 million in Q4 FY17 compared to $79.7 million in the previous year's corresponding quarter.

Bruker's cash and cash equivalents balance was $325.0 million as on December 31, 2017, compared to $342.4 million as on December 31, 2016. Furthermore, the Company's long-term debt stood at $415.6 million as on December 31, 2017, compared to $391.6 million as on December 31, 2016.

Outlook

In its guidance for FY18, Bruker expects a revenue growth of approximately 7%, which includes an organic revenue growth of approximately 3%, and a foreign currency revenue tailwind of approximately 4%. The Company's non-GAAP operating margin is expected to improve by 50 bps and 80bps for FY18. The management further anticipates non-GAAP earnings per share to be in the range of $1.34 and $1.38 during FY18, rising 11% to 14% y-o-y.

Dividend

In a separate press on February 20, 2018, Bruker's Board of Directors announced a quarterly cash dividend in the amount of $0.04 per share on its common stock. The dividend will be paid on March 23, 2018, to stockholders of record as of March 06, 2018.

Stock Performance Snapshot

March 13, 2018 - At Tuesday's closing bell, Bruker's stock fell 1.98%, ending the trading session at $30.13.

Volume traded for the day: 1.08 million shares, which was above the 3-month average volume of 508.40 thousand shares.

Stock performance in the previous six-month period – up 0.94%; and past twelve-month period – up 26.86%

After yesterday's close, Bruker's market cap was at $4.60 billion.

Price to Earnings (P/E) ratio was at 32.26.

The stock has a dividend yield of 0.53%.

The stock is part of the Healthcare sector, categorized under the Medical Laboratories & Research industry.

Active-Investors :

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 492981

Source URL: https://marketersmedia.com/free-post-earnings-research-report-brukers-q4-top-line-grew-12-8-y-o-y-outshone-expectations/314227

Source: AccessWire

Release ID: 314227

Latest Releases

Our Client

Subscribe and Recieve exclusive insider tips and tricks on Press Release.

Follow Us

Copyright © 2012 - 2018 MarketersMedia – Press Release Distribution Services – News Release Distribution Services. All Rights Reserved.

Powered by Semantics BigData Analytics (SBDA).